Research programme: botulinum toxins - Ipsen Bioinnovation

Drug Profile

Research programme: botulinum toxins - Ipsen Bioinnovation

Alternative Names: botulinum neurotoxins; SXN

Latest Information Update: 15 Dec 2016

Price : $50

At a glance

  • Originator Syntaxin
  • Developer Ipsen Bioinnovation
  • Class Bacterial proteins; Bacterial toxins; Botulinum toxins; Recombinant proteins
  • Mechanism of Action Acetylcholine inhibitors; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 15 Dec 2016 Preclinical development is ongoing United Kingdom (Ipsen pipeline, December 2016)
  • 16 Jul 2016 No recent reports of development identified for research development in Undefined in United Kingdom
  • 15 Jul 2013 Ipsen acquires Syntaxin
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top